Xian Wu

Xian Wu

Auto-generated profile, based on publicly available information

Xian Wu

Department of Ultrasound, West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
XWXian Wu
Xian Wu
GZGuiqiu Zhao
Guiqiu Zhao
JLJing Lin
Jing Lin
NJNan Jiang
Nan Jiang
CLCui Li
Cui Li
YZYan Zhang
Yan Zhang

4 June 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
CWCong Wang
Cong Wang
ZLZhenghuan Liu
Zhenghuan Liu
ZXZhihui Xu
Zhihui Xu
XWXian Wu
Xian Wu
Dongyang ZhangDongyang Zhang
Dongyang Zhang
JWJianqin Wei
Jianqin Wei
Chemokine ligand 25 (CCL25) and chemokine receptor 9 (CCR9) are important regulators of migration, proliferation and apoptosis in leukocytes and cancer cells. Blocking of the CCR9/CCL25 signal has been demonstrated to be a potential novel cancer therapy. Research into CCR9 and CCL25 has revealed their associated upstream and downstream signaling pathways; CCR9 is regulated by several immunological factors, including NOTCH, interleukin 2, interleukin 4 and retinoic acid. NOTCH in particular, has been revealed to be a crucial upstream regulator of CCR9. Furthermore, proteins including matrix metalloproteinases, P‑glycoprotein, Ezrin/Radixin/Moesin and Livin are regulated via phosphatidylinositol‑3 kinase/ protein kinase B, which are in turn stimulated by CCR9/CCL25. This is a review of the current literature on the functions and signaling pathways of CCR9/CCL25.